Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

Abstract Background Pegylated interferon (PEG-IFN) alfa-2b is recommended for chronic hepatitis B (CHB). We aimed to investigate the sustainability of off-treatment responses among Chinese HBeAg-positive CHB patients treated with PEG-IFN alfa-2b from a randomized trial. Methods Eligible Chinese pati...

Full description

Bibliographic Details
Main Authors:	Jian Sun, Huiguo Ding, Guofeng Chen, Guiqiang Wang, Lai Wei, Jiming Zhang, Qing Xie, Mobin Wan, Hong Tang, Shijun Chen, Zhiliang Gao, Yuming Wang, Dazhi Zhang, Wenxiang Huang, Jifang Sheng, Qin Ning, Dongliang Yang, Jian Lu, Chen Pan, Yuxiu Yang, Jue Wang, Chuanzhen Sun, Qixin Wang, Jinlin Hou
Format:	Article
Language:	English
Published:	BMC 2019-05-01
Series:	BMC Gastroenterology
Subjects:	Chronic hepatitis B Peg-interferon Long-term follow-up Sustained serological response Sustained combined clinical response
Online Access:	http://link.springer.com/article/10.1186/s12876-019-0981-5

Similar Items

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
by: Cheng-Yuan Peng, et al.
Published: (2015-04-01)

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
by: Guillermo Cabrera Álvarez, et al.
Published: (2011-10-01)

Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C
by: Chao-Hung Hung, et al.
Published: (2016-04-01)

Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a
by: Wen Jia, et al.
Published: (2019-05-01)

The Predictive Factors for Favorable Outcomes of Peginterferon and Ribavirin Combination Therapy in HCV-Infected Patients
by: Javad Moayedi, et al.
Published: (2020-08-01)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
Published: (2006-01-01)

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
by: Ruochan Chen, et al.
Published: (2021-07-01)

Study of hepatic histomorphology in HBeAg+ and HBeAg− patients with CHB: Experience from Bangladesh
by: Ayub Al Mamun, et al.
Published: (2013-01-01)

Mitogen-activated protein kinase eight polymorphisms are associated with immune responsiveness to HBV vaccinations in infants of HBsAg(+)/HBeAg(−) mothers
by: Meng Zhuo Cao, et al.
Published: (2018-06-01)

Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients
by: Ming-Yen Hsieh, et al.
Published: (2012-02-01)

Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B
by: I-Cheng Lee, et al.
Published: (2021-09-01)

The effect of patients with chronic hepatitis B HBeAg（+）with poor response to treatment by converting to sequential treatment with tenofovir dipivoxil
by: Zhi-Xiong Liao
Published: (2020-03-01)

Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010
by: Sener Barut, et al.

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks
by: Xiaomei Wang, et al.
Published: (2020-10-01)

HBeAg-negative chronic hepatitis
by: M M Ibragimova, et al.
Published: (2004-02-01)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
by: Osamu Yokosuka, et al.
Published: (2012-08-01)

Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion.
by: Yen-Ling Ko, et al.
Published: (2015-01-01)

Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis B.
by: Thilde Nordmann Winther, et al.
Published: (2013-01-01)

Results of peginterferon alpha-2a treatment in patients with chronic hepatitis B in the Western part of Romania
by: Roxana Șirli, et al.
Published: (2016-12-01)

Relationship of T Cell Immunity and HBeAg Loss During Telbivudine Treatment in Patients with HBeAg-positive Chronic Hepatitis B
by: Yih-Tsong Shiau, et al.
Published: (2014)

The Change of Quantitative of HBeAg Can Predict the Efficacy of Peg-IFN-α 2a in HBeAgpositive CHB Patients
by: Ji Yong-jian, et al.
Published: (2013-09-01)

Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia
by: Božić Milena, et al.
Published: (2012-01-01)

Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B
by: Chao-Wei Hsu, et al.
Published: (2018-07-01)

Prediction of the Response to Pegylated Interferon α-2a in Patients with HBeAg Positive Chronic Hepatitis B through Decline of Serum HBV DNA and Hepatitis B Virus Surface Antigen at Week 4
by: Zheng Jian-ming, et al.
Published: (2012-12-01)

Sustainability analysis, report and statement
by: Jordaan, G., et al.
Published: (2015)

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon α
by: Hu Yao-ren, et al.
Published: (2014-03-01)

Significance of changes in hepatic histology from patients with HBeAg(+) or HBeAg(-) chronic hepatitis B and normal or mildly elevated alanine aminotransferase
by: LAN Lin
Published: (2015-04-01)

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
by: Lai Wei, et al.
Published: (2018-01-01)

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype
by: Tatsuo Kanda, et al.
Published: (2015-07-01)

A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin
by: Ching-Sheng Hsu, et al.
Published: (2014-10-01)

Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy
by: Shingo Nakamoto, et al.
Published: (2015-09-01)

Study on Post-Treatment Relapse in HBeAg Positive CHB Patients.
by: Junfeng Lu, et al.
Published: (2015-01-01)

Viral Biomarkers in Chronic HBeAg Negative HBV Infection
by: Emilia Hadziyannis, et al.
Published: (2018-09-01)

Develop genetic programming to predict the state of seroconversion of HBeAg
by: Chu-Yu Chin, et al.
Published: (2005)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
by: Byung-Cheol Song, et al.
Published: (2014-12-01)

Implementation of sustainable marketing concept in a company as a prerequisite to survive on global market
by: Petković Nebojša, et al.
Published: (2019-01-01)

CORPORATE SOCIAL RESPONSIBILITY- A NEW PERSPECTIVE FOR SMEs IN ROMANIA
by: Oana POPA
Published: (2012-01-01)

Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20–30 Times the ULN)
by: Yang Zhang, et al.
Published: (2019-01-01)

The Impact of HBeAg Index Value on the Response to Lamivudine Treatment in Chronic Hepatitis B Patients
by: Chia-Chi Wang, et al.
Published: (2005)

Lamivudine therapy in HBeAg negative chronic hepatitis B patients
by: E. Guclu, et al.
Published: (2014-04-01)